Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the third quarter of 2018. “We are pleased to report the results of our third
Toggle Summary Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
-- Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 -- SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc.

SEC Filings


There are currently no events to display.

Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Ken Cacciatore
BMO Capital Markets
Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services

IR Contact

Media Contact